Gemina Laboratories Ltd.
GLABF
$0.7362
$0.0060.82%
| Weiss Ratings | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.07 | |||
| Price History | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 8.26% | |||
| 30-Day Total Return | 71.21% | |||
| 60-Day Total Return | 33.83% | |||
| 90-Day Total Return | 162.93% | |||
| Year to Date Total Return | 34.79% | |||
| 1-Year Total Return | 88.77% | |||
| 2-Year Total Return | 40.23% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -5.17% | |||
| 52-Week Low % Change | 210.72% | |||
| Price | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.77 | |||
| 52-Week Low Price | $0.24 | |||
| 52-Week Low Price (Date) | Oct 21, 2024 | |||
| 52-Week High Price (Date) | Mar 11, 2025 | |||
| Valuation | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 54.24M | |||
| Enterprise Value | 55.22M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.03 | |||
| Earnings Per Share Growth | -50.44% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -21.93 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.74 | |||
| Enterprise Value/EBITDA (TTM) | -21.15 | |||
| Enterprise Value/EBIT | -21.04 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 74.51M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 3600 Gilmore Way Burnaby, BC V5G 4W8 | |||
| Website | www.geminalabs.com | |||
| Country | Canada | |||
| Year Founded | 2017 | |||
| Profitability | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -142.04% | |||
| Return on Equity | -- | |||
| Income Statement | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -2.61M | |||
| EBIT (TTM) | -2.62M | |||
| Net Income (TTM) | -2.51M | |||
| Net Income Avl. to Common (TTM) | -2.51M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 26.42% | |||
| EPS Diluted (TTM) | -0.03 | |||
| EPS Diluted Growth (Q YOY) | 27.35% | |||
| Balance Sheet | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 29.90K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 119.90K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -2.48M | |||
| Current Ratio (Q) | 0.035 | |||
| Book Value Per Share (Q) | -$0.03 | |||
| Total Assets (Q) | 1.10M | |||
| Total Current Liabilities (Q) | 3.44M | |||
| Total Debt (Q) | 1.05M | |||
| Total Liabilities (Q) | 3.58M | |||
| Total Common Equity (Q) | -2.48M | |||
| Cash Flow | GLABF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 12.00K | |||
| Cash from Financing (TTM) | 939.40K | |||
| Net Change in Cash (TTM) | 27.90K | |||
| Levered Free Cash Flow (TTM) | -1.20K | |||
| Cash from Operations (TTM) | -923.60K | |||
